TR research associated with 'A multicenter Phase II basket-type clinical trial to evaluate efficacy and safety of TAS-120 in patients with advanced solid malignancies with FGFR alterations in circulating tumor DNA (TiFFANY study)'
Latest Information Update: 03 Jul 2023
At a glance
- Drugs Futibatinib (Primary)
- Indications Solid tumours
- Focus Biomarker; Therapeutic Use
- Acronyms TiFFANY study; TiFFANY test
- 06 Jun 2023 Results evaluating the efficacy and safety of futibatinib, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 10 Nov 2022 Planned End Date changed from 31 Mar 2024 to 31 May 2025.
- 10 Nov 2022 Planned initiation date changed from 17 Jun 2019 to 1 Jun 2019.